Drugs Made In America Acquisition Corp. (DMAA)
Drugs Made In America Acquisition will go public soon, but the exact IPO date is still unknown.
IPO Price
$10.00
Shares Offered
50,000,000
Deal Size
$500.00M
Chart not available yet
Data will show when the stock starts trading.
| Market Cap | 756.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 75.69M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About DMAA
Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. We intend to focus our search for business combination targets in the pharmaceutical industry. [Read more]
Industry Shell Companies
Sector Financials
Founded 2024
Country United States
Stock Exchange NASDAQ
Ticker Symbol DMAA
News
SPAC Drugs Made In America Acquisition files for a $500 million IPO
Drugs Made In America Acquisition, a blank check company targeting pharmaceutical businesses in the US, filed on Thursday with the SEC to raise up to $500 million in an initial public offering.
3 months ago - Renaissance Capital
Drugs Made In America Acquisition IPO Registration Document (S-1)
Drugs Made In America Acquisition has filed to go public with an IPO on the NASDAQ.
3 months ago - SEC